PSEUDOMYXOMA
PERITONEI (PMP)
PMP fills the peritoneal cavity with gelatinous mucus from a mucin-secreting appendiceal tumour. Despite seemingly overwhelming abdominal disease, low-grade PMP is one of the most curable peritoneal malignancies — with 10-year survival exceeding 80% after complete CRS-HIPEC at a specialist centre.
analyticsAt a Glance
- check_circlePMP arises almost exclusively from the appendix — typically a low-grade mucinous neoplasm (LAMN) that ruptures and seeds the peritoneum
- check_circleThe 'jelly belly' appearance — a peritoneal cavity filled with gelatinous mucus — is pathognomonic
- check_circleLow-grade PMP (DPAM): 10-year OS >80% with complete CRS-HIPEC; high-grade (PMCA): 5-year OS ~30%
- check_circlePMP is treated at the same specialist peritoneal oncology centres that perform CRS-HIPEC for colorectal and ovarian cancer
What Is Pseudomyxoma Peritonei and Where Does It Come From?
Pseudomyxoma peritonei literally means 'false mucinous tumour of the peritoneum.' It is characterised by the accumulation of large volumes of gelatinous or semi-solid mucin throughout the peritoneal cavity — produced by mucin-secreting tumour cells that have seeded from a ruptured appendiceal mucinous neoplasm. The volumes of mucin can be extraordinary: some patients at diagnosis have 10–20 litres of jelly-like material filling the abdominal cavity.
“PMP patients sometimes wait years for a diagnosis — their expanding abdomen attributed to weight gain, ascites, or ovarian disease before the true appendiceal origin and 'jelly belly' nature of the condition is identified.”
The Appendiceal Origin
Over 90% of PMP originates from the appendix — specifically from a low-grade appendiceal mucinous neoplasm (LAMN) that develops in the appendiceal wall, distends the appendix with mucin, and eventually ruptures — either spontaneously or during appendicectomy — releasing mucin-producing cells into the peritoneal cavity. A small number arise from the ovary, colon, urachus, or other mucinous structures.
Why PMP Fills the Belly Slowly
PMP is not a rapidly proliferating cancer in its low-grade form — the tumour cells produce mucin slowly, and the condition typically progresses over years rather than weeks. Patients often present with symptoms of abdominal distension, hernia, or incidental finding on appendicectomy for apparent 'appendicitis' — only for the mucinous material encountered to trigger the PMP diagnosis.
PMP Histological Classification and Prognosis
The histological grade of PMP is the most important prognostic determinant — particularly distinguishing low-grade (DPAM) from high-grade (PMCA) disease. The PSOGI (Peritoneal Surface Oncology Group International) consensus classification is the current standard.
| PSOGI Grade | Former Name | Key Features | 5-Year OS | 10-Year OS |
|---|---|---|---|---|
| Low-grade mucinous carcinoma peritonei (LGMCP) | DPAM (Disseminated Peritoneal Adenomucinosis) | Abundant extracellular mucin; minimal cytological atypia; scant cellularity; no signet ring cells | >85–90% | >80% |
| High-grade mucinous carcinoma peritonei (HGMCP) | PMCA (Peritoneal Mucinous Carcinomatosis) | More cellular; significant atypia; intestinal-type or mucinous adenocarcinoma features | ~50% | ~25–30% |
| HGMCP with signet ring cells | PMCA-I/D (with signet ring component) | Signet ring cells present (>10%); most aggressive subtype; poor differentiation | ~15–20% | <10% |
| Acellular mucin only | N/A — diagnostic category | No tumour cells in mucin — prognostic significance uncertain; generally excellent prognosis if complete removal achieved | >90% | >85% |
How PMP Is Diagnosed and Staged
PMP has a characteristic appearance on imaging but requires histological confirmation from biopsied tissue before treatment planning.
- 1
CT Abdomen and Pelvis
The hallmark CT finding of PMP is 'scalloping' of liver and spleen surfaces — the gelatinous mucin indents the organ surfaces in a characteristic pattern. The omentum is typically replaced by a mucinous 'omental cake'. Ascites-like low-density material fills the peritoneal cavity in large volumes. CT provides the initial PCI estimate and identifies hepatic or extra-abdominal involvement.
- 2
MRI Peritoneal Protocol
MRI is more sensitive than CT for distinguishing mucin from ascites, characterising the extent of mucinous deposits on bowel and mesenteric surfaces, and assessing small-bowel involvement. Recommended at specialist centres for pre-operative planning in PMP.
- 3
Tumour Markers
CEA, CA 19-9, and CA-125 are measured at baseline. Elevated levels are common in PMP and provide a monitoring baseline — though markedly elevated CEA with extensive disease does not necessarily imply high-grade histology.
- 4
Histological Confirmation
Tissue diagnosis is essential before CRS-HIPEC is planned. In patients discovered incidentally at appendicectomy (mucinous material found), the appendiceal specimen provides diagnosis. In patients with established peritoneal disease, CT-guided biopsy of an omental deposit or diagnostic laparoscopy provides tissue.
- 5
Specialist Multidisciplinary Review
PMP should always be reviewed at a specialist peritoneal oncology MDT — not at a general oncology tumour board. The rarity of the condition means most generalists have limited experience, and management decisions differ substantially from standard bowel cancer protocols.
PMP Outcomes After CRS-HIPEC: Published Data
The following data reflect published outcomes from specialist peritoneal oncology centres with specific PMP experience — demonstrating why CRS-HIPEC is the standard of care for this condition.
Survival by Histological Grade — PSOGI International Registry
Source: PSOGI international registry (Chua et al., Ann Surg Oncol 2012) and Moran et al. updates
- Low-grade (LGMCP): 5-year OS87%
- Low-grade (LGMCP): 10-year OS80%
- High-grade (HGMCP): 5-year OS52%
- HGMCP with signet ring cells: 5-year OS18%
Impact of Completeness of Cytoreduction (CC Score) on PMP Survival
Pooled from Moran et al. (Manchester) and Sugarbaker (Washington) series; all histologies combined
- CC-0 (no residual disease): 5-year OS74%
- CC-1 (≤2.5 mm residual): 5-year OS58%
- CC-2 (>2.5 mm residual): 5-year OS32%
Why PMP Has the Best Prognosis of All Peritoneal Malignancies
Low-grade PMP occupies a uniquely favourable position in peritoneal oncology — a condition where very extensive peritoneal disease is nonetheless technically resectable and associated with long-term survival.
PMP (Low-Grade): Why It Is Treatable
- Mucin is non-invasive — does not penetrate organsPMP mucin accumulates on peritoneal surfaces but does not invade into organ parenchyma or the bowel wall — it pushes against structures rather than infiltrating them, making the mucin removable in large sheets.
- Slow tumour growth allows extensive surgeryThe slow doubling time of low-grade PMP means that even very high PCI disease can be completely resected in an experienced surgeon's hands — operating for 8–12 hours to remove large volumes of mucin and mucin-laden tissue.
- No haematogenous spread until lateLow-grade PMP almost never spreads to the liver parenchyma, lungs, or distant lymph nodes — it remains a peritoneal-surface malignancy throughout its natural history, making it entirely addressable with peritoneal-surface surgery.
- Chemotherapy response is modestPMP does not respond well to systemic chemotherapy — making CRS-HIPEC the only effective treatment option and strengthening its role as the definitive management.
Other Peritoneal Malignancies: Key Differences
- Colorectal peritoneal metastasesCRC deposits are invasive — they infiltrate the peritoneal surface and can invade bowel wall and mesentery. Median OS 30–40 months after CC-0, compared to >80 months for low-grade PMP.
- Ovarian peritoneal diseaseOvarian cancer deposits are often small and numerous — covering the entire peritoneal surface in small implants that are technically harder to clear completely than PMP mucin.
- Gastric peritoneal metastasesGastric peritoneal disease progresses rapidly and is associated with signet ring histology in many cases — the worst-prognosis peritoneal malignancy regardless of treatment.
- High-grade PMP with signet ring cellsEven within PMP, signet ring cell component (HGMCP-S) carries a dramatically worse prognosis — 5-year OS of only 15–20% — and should be managed differently from low-grade disease.
More from the Peritoneal Oncology Resource Library
Continue exploring peritoneal oncology — from what peritoneal carcinomatosis is to CRS procedure details and other tumour types.
Frequently Asked Questions
Common questions from PMP patients and families navigating diagnosis and treatment decisions.
About PMP
I was told I have 'jelly belly' — is this the same as PMP and is it cancer?
Yes — 'jelly belly' is the colloquial term for pseudomyxoma peritonei, describing the gelatinous mucus that accumulates in the peritoneal cavity. Whether it is classified as 'cancer' depends on histological grade. Low-grade PMP (LGMCP/DPAM) behaves more like a slow-growing benign-to-borderline mucinous process — it rarely metastasises beyond the peritoneal cavity and does not behave like conventional adenocarcinoma, which is why some specialists prefer the term 'borderline malignancy.' High-grade PMP (HGMCP) is a true malignancy with invasive features. The distinction matters enormously for prognosis and treatment urgency, and requires formal histopathology review at a specialist centre.
My surgeon removed my appendix for appendicitis and found mucinous material — what happens next?
This is the most common PMP presentation pathway. If mucinous material was found at appendicectomy, the most important next steps are: (1) specialist pathological review of the appendix specimen at a centre with peritoneal oncology expertise — the distinction between LAMN, HAMN, and mucinous adenocarcinoma determines prognosis and urgency; (2) a CT abdomen and pelvis to assess for peritoneal disease; (3) review of your case at a specialist peritoneal oncology MDT. Even if the CT shows limited or no peritoneal deposits, specialist follow-up is essential because PMP can progress slowly after an apparently clean appendicectomy. CancerFax can facilitate rapid referral to a specialist PMP centre.
Can CRS-HIPEC cure PMP, or will it always come back?
For low-grade PMP (LGMCP/DPAM) with complete cytoreduction (CC-0), published 10-year overall survival rates exceed 80% at the highest-volume centres — and some patients with complete CC-0 resection have remained disease-free at 15–20 years. 'Cure' is a cautious term in oncology, but for low-grade PMP with no residual disease after complete CRS-HIPEC, long-term remission is a realistic and achievable goal. The recurrence rate at 5 years is approximately 30–40% even with CC-0 resection, but many recurrences are slow-growing and amenable to repeat CRS — making PMP a disease where multiple operations over decades can still achieve excellent long-term outcomes.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Diagnosed with PMP? Specialist Access Matters.
PMP is rare — most general oncologists and surgeons encounter it rarely. CancerFax connects PMP patients with specialist peritoneal oncology surgeons at high-volume CRS-HIPEC centres in China and India who have specific experience with mucinous appendiceal neoplasms and PMP.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.